Norman Wasel

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet

Craig L. Leonardi, Richard G. Langley, Kim Papp et al. · Archives of Dermatology · 2010 · 109 citations

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

Kim Papp, Robert Bissonnette, L. Rosoph et al. · The Lancet · 2008 · 87 citations

Inflammation, Immunology, Clinical Trials +5

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis

Robert Bissonnette, David M. Pariser, Norman Wasel et al. · Journal of the American Academy of Dermatology · 2016 · 82 citations · Full text

Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.

Carrie Brodmerkel, Eric Wadman, Richard G. Langley et al. · PubMed · 2013 · 69 citations